See more : PICC Property and Casualty Company Limited (PPCCF) Income Statement Analysis – Financial Results
Complete financial analysis of Trevena, Inc. (TRVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trevena, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Catalyst Bancorp, Inc. (CLST) Income Statement Analysis – Financial Results
- Pacific Century Premium Developments Limited (0432.HK) Income Statement Analysis – Financial Results
- Qingdao Doublestar Co.,Ltd (000599.SZ) Income Statement Analysis – Financial Results
- Dubai Investments PJSC (DIC.AE) Income Statement Analysis – Financial Results
- Teamo Productions HQ Limited (TPHQ.NS) Income Statement Analysis – Financial Results
Trevena, Inc. (TRVN)
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.13M | -418.00K | 567.00K | 3.07M | 31.00K | 5.73M | 0.00 | 3.75M | 6.25M | 0.00 | 134.98K | 807.60K | 2.42M |
| Cost of Revenue | 1.67M | 3.02M | 954.00K | 182.00K | 108.00K | 0.00 | 490.00K | 0.00 | 44.07M | 40.55M | 18.76M | 13.29M | 0.00 |
| Gross Profit | 1.46M | -3.44M | -387.00K | 2.89M | -77.00K | 5.73M | -490.00K | 3.75M | -37.82M | -40.55M | -18.63M | -12.49M | 2.42M |
| Gross Profit Ratio | 46.56% | 822.01% | -68.25% | 94.07% | -248.39% | 100.00% | 0.00% | 100.00% | -605.18% | 0.00% | -13,800.00% | -1,546.24% | 100.00% |
| Research & Development | 16.33M | 18.21M | 13.43M | 13.12M | 13.29M | 15.82M | 48.97M | 89.96M | 44.07M | 40.55M | 18.76M | 13.29M | 15.11M |
| General & Administrative | 0.00 | 0.00 | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.41M | 34.73M | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Other Expenses | 0.00 | 2.71M | 337.00K | 416.00K | 2.25M | 459.00K | 614.00K | -711.00K | 92.93K | 184.02K | 1.25K | 122.79K | 0.00 |
| Operating Expenses | 38.41M | 52.94M | 51.54M | 32.37M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Cost & Expenses | 38.41M | 55.96M | 52.49M | 32.55M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Interest Income | 2.25M | 451.00K | 162.00K | 240.00K | 418.00K | 1.00M | 679.00K | 743.00K | 331.21K | 17.37K | 884.00 | 754.00 | 3.54K |
| Interest Expense | 0.00 | 1.26M | 1.00K | 29.00K | 931.00K | 2.23M | 2.78M | 1.74M | 334.37K | 70.65K | 149.76K | 193.74K | 74.22K |
| Depreciation & Amortization | 893.00K | 864.00K | 841.00K | 830.00K | 863.00K | 645.00K | 490.00K | 246.00K | 207.90K | 239.39K | 706.78K | 787.52K | 801.58K |
| EBITDA | -35.29M | -55.51M | -51.08M | -28.66M | -25.61M | -28.43M | -68.12M | -101.01M | -50.62M | -49.71M | -22.64M | -14.65M | -14.95M |
| EBITDA Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -74,961.29% | -482.27% | 0.00% | -2,727.55% | -809.94% | 0.00% | -16,770.17% | -1,820.09% | -617.21% |
| Operating Income | -35.29M | -56.38M | -51.93M | -29.49M | -26.58M | -30.50M | -70.39M | -102.28M | -50.62M | -49.95M | -23.35M | -15.61M | -15.75M |
| Operating Income Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -85,741.94% | -532.07% | 0.00% | -2,727.55% | -809.94% | 0.00% | -17,295.37% | -1,932.90% | -650.46% |
| Total Other Income/Expenses | -4.68M | 2.71M | 337.00K | 416.00K | 1.71M | 459.00K | -3.25M | -711.00K | 92.76K | 249.13K | 93.85K | -25.62K | -59.79K |
| Income Before Tax | -39.97M | -53.67M | -51.59M | -29.07M | -24.87M | -30.04M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Income Before Tax Ratio | -1,279.07% | 12,839.71% | -9,098.41% | -947.18% | -80,229.03% | -524.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| Income Tax Expense | 318.00K | -2.71K | -428.00K | 300.00K | 3.19M | 745.00K | 3.39M | -246.00K | -207.90K | 254.67K | 151.00K | 316.53K | 74.22K |
| Net Income | -40.29M | -53.67M | -51.16M | -29.37M | -28.06M | -30.78M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Net Income Ratio | -1,289.25% | 12,839.07% | -9,022.93% | -956.96% | -90,503.23% | -537.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| EPS | -54.51 | -14.88 | -7.82 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| EPS Diluted | -54.51 | -14.88 | -7.77 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| Weighted Avg Shares Out | 739.05K | 3.61M | 6.54M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
| Weighted Avg Shares Out (Dil) | 739.05K | 3.61M | 6.58M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner
Trevena Awarded OLINVYK Agreement with Premier, Inc.
CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement...
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12th Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in...
Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial...
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in blood pressure reported CHESTERBROOK, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) --...
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into respiratory compromise rates
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study
Source: https://incomestatements.info
Category: Stock Reports